All In Biotech

Drug Trial Radar · NCT05020457

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Chemotherapy in the Treatment of EGFR WT and ALK WT Recurrent and Metastatic Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

69

Actual

Start

Dec 7, 2021

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Sponsor type
Industry
First posted
Aug 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multi-center, open label phase II clinical study is performed in patients with locally advanced or metastatic EGFR wild-type ALK wild-type non-small cell lung cancer progressed on prior anti-PD-1 mab ± platinum-based chemotherapy. This study is investigating the safety and efficacy of SI-B001 at optimal combination dose with chemotherapy in patients.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • SI-B001Drug

    SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended), if SI-B001 and chemotherapy are used on the same day, the infusion of chemotherapeutic drugs should be continued after the completion of SI-B001 infusion.

  • AP or TPDrug

    AP or TP should be administered immediately after SI-B001 is completed. The administration of AP or TP should refer to the drug instructions and standard usage.

  • DocetaxelDrug

    Docetaxel should be administered immediately after SI-B001 is completed. The administration of Docetaxel should refer to the drug instructions and standard usage.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: Up to approximately 24 months
  2. Optimal combination dose (only IIa)Time frame: Up to approximately 24 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Sun Yat-sen University Cancer Center (SYSUCC)

    Guangzhou, Guangdong, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The Second Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • TaiZhou Hospital of Zhejiang Province

    Taizhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.